文献速递神经肿瘤

次全切除后无功能垂体大腺瘤的经验性 versus 进展引导立体定向放射外科

Empirical versus progression-guided stereotactic radiosurgery for non-functional pituitary macroadenomas after subtotal resection.
PubMed 文献 · J Neurooncol · 2019-01-12

该回顾性研究比较了次全切除后无功能垂体大腺瘤患者接受经验性立体定向放射外科(SRS)与进展引导SRS的风险与获益。共纳入106例患者,经验性SRS组46例,进展引导SRS组60例。经验性SRS组肿瘤控制率(95.65% vs. 83.33%,p=0.047)和无进展生存率(p=0.015)均高于进展引导SRS组,两组新发视野缺损、颅神经病变和内分泌病变发生率相当。

要点

  • 经验性SRS组肿瘤控制率95.65%,进展引导SRS组83.33%,差异有统计学意义(p=0.047)。
  • 经验性SRS组无进展生存率高于进展引导SRS组(p=0.015)。
  • 两组新发视野缺损、颅神经病变和内分泌病变发生率相当。

核心结论

  • 对于次全切除后的残余无功能垂体大腺瘤,经验性SRS相比进展引导SRS具有更高的肿瘤控制率和无进展生存率,两组新发垂体功能减退和颅神经病变发生率相当。

研究设计与样本

  • 回顾性研究,纳入1999年至2014年间接受次全手术切除后SRS的无功能垂体大腺瘤连续患者,最终分析106例,分为经验性SRS组(46例)和进展引导SRS组(60例)。

主要发现

  • 总体肿瘤控制率为88.7%。
  • 经验性SRS组肿瘤控制率95.65% vs. 进展引导SRS组83.33%(p=0.047)。
  • 经验性SRS组无进展生存率高于进展引导SRS组(p=0.015)。
  • 经验性SRS组SRS后3年、5年、10年 actuarial 无进展生存率分别为93.2%、93.2%、81.5%;进展引导SRS组分别为86.4%、82.1%、68.4%。
  • 两组新发视野缺损、颅神经病变和内分泌病变发生率相当。

关键数值与推荐

  • 肿瘤反应分类:退缩为肿瘤体积缩小≥10%;稳定为肿瘤体积变化<10%;进展为肿瘤体积增大≥10%;肿瘤控制包括稳定和退缩。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There is a lack of consensus regarding whether if residual non-functional macroadenomas (NFM) should undergo empirical stereotactic radiosurgery (SRS) or be monitored until tumor progression before SRS treatment. The aim of this study is to compare the risks and benefits of empirical versus progression-guided SRS for NFM after subtotal resection. METHODS: This is a retrospective study of consecutive NFM patients who subtotal surgical resection followed by SRS between 1999 and 2014. Patients were dichotomized into two groups: empirical SRS (SRS without evidence of tumor progression) and progression-guided SRS (SRS after demonstration of tumor progression) groups. Tumor response was categorized into: (1) regression, ≥ 10% decrease in tumor volume; (2) stable, < 10% increase or decrease in tumor volume; and (3) progression, ≥ 10% increase in tumor volume. Tumor control comprised stable tumor response and tumor regression. RESULTS: Of the 112 patients who underwent SRS for NFM, 106 patients were treated for residual NFM after surgical resection, and included in the final analysis. The empirical SRS and progression-guided SRS groups comprised 46 and 60 patients, respectively. Overall tumor control rate was 88.7%. Higher rate of tumor control was achieved in the empirical SRS group compared to the progression-guided SRS group (95.65% vs. 83.33%, p = 0.047). Rates of new visual field deficit, cranial neuropathy and endocrinopathy were comparable between the two groups. Empirical SRS group had higher rates of progression-free survival compared to progression-guided SRS group (p = 0.015). Actuarial progression-free survival rates for the empirical SRS group were 93.2%, 93.2%, and 81.5% at 3, 5, and 10 years after SRS. Actuarial progression-free survival rates for the progression-guided SRS were 86.4%, 82.1%, and 68.4% at 3, 5, and 10 years after SRS. CONCLUSION: Empirical SRS offers higher rates of tumor control and progression-free survival compared to progression-guided SRS in patients with residual NFM after surgical resection. Rates of new hypopituitarism and cranial neuropathies were comparable between the two groups.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Lee CC, Yang HC, Chen CJ, et al. Empirical versus progression-guided stereotactic radiosurgery for non-functional pituitary macroadenomas after subtotal resection. J Neurooncol. 2019. PMID: 30635763. doi:10.1007/s11060-019-03095-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。